Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's New R&D Tax Credit Expected To Inject Funds Into Local Biotech Industry - And Multinational Subsidiaries?

This article was originally published in PharmAsia News

Executive Summary

MELBOURNE, Australia - Many in the Australian life sciences industry view the nation's new R&D Tax Credit, which became law in August 2011 with the passing of the Tax Laws Amendment (Research and Development) Bill 2010, as a marked improvement on the R&D Tax Concession it replaces

You may also be interested in...



Australia Ramps Up Early Research Via Medical Research Commercialization Fund

Funding for early-stage research has been a huge problem in Australia until recently, and new funding mechanisms have come just in time as research begun a decade ago moves into development.

Australia Ranked As Second Most Expensive Country For Clinical Trials; Medicines Australia Calls For Reform

A strong currency and cumbersome rules have contributed to Australia becoming the second-most expensive country for clinical trials, and neighboring countries are taking advantage.

What Financial Crisis? Australian Biotech Enters Golden Era (Part 1 of 2)

PERTH, Australia - Australia's biotech sector has entered a golden era, with its top 20 companies now maturing, for the first time bringing products to late-stage development, and looking to commercialize

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel